DBDominika Bieszczad

Dominika Bieszczad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dominika Bieszczad has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    DIGITAL DEMENTIA IN CHILDREN AND ADOLESCENTS: SYMPTOMS, RISK FACTORS AND PREVENTION STRATEGIES. A NARRATIVE REVIEW

    by Patrycja Felisiak, Magdalena Barszczewska, Dominika Bieszczad, Zofia Botto, Dominika Kowalczyk, Klaudia Krystek, Barbara Reizer, Marzena Swójnóg, Dominik Andrzej Ślazyk, Zofia Śliwa

    Children and adolescents, as the new generation of avid technology users, are often able to use it to their great benefit. However, it comes with the cost of being exposed to a variety of health risks, cognitive health being one of the main areas affected. As developing brains are the most susceptible to these risks, Manfred Spitzer’s concept of digital dementia seems as relevant as ever nowadays. In the present study, we analyse over a hundred published works with the goal of creating a compact yet comprehensive summary of existing knowledge on digital dementia in the population of infants, preschoolers, schoolchildren and adolescents. Findings suggest that multiple cognition areas are affected, with memory, critical thinking and problem solving being among the most alarming. While the role of parents as guardians of digital health cannot be overstated, other factors such as environment and unmodifiable traits also play a role. For preventing and mitigating this problem, a collaborative effort of caretakers but also teachers, doctors and policy makers is most urgently needed. We conclude that digital dementia among youth is a common problem, therefore recognising symptoms early, minimising risks and preventing its progression will prove beneficial to whole generations.

  • Open Access

    SHRINKING LUNG SYNDROME IN SYSTEMIC LUPUS ERYTHEMATOSUS-CLINICAL AND THERAPEUTIC CHALLENGES

    by Barbara Reizer, Zofia Botto, Marzena Swojnóg, Klaudia Krystek, Patrycja Felisiak, Dominika Kowalczyk, Dominika Bieszczad, Magdalena Barczewska, Zofia Śliwa, Dominik Andrzej Ślazyk

    Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem involvement. One of its rare but clinically significant complications is the shrinking lung syndrome (SLS), which affects less than 1% of patients and presents diagnostic and therapeutic challenges. Aim: This paper aims to present a comprehensive overview of shrinking lung syndrome as a rare manifestation of SLE, with a focus on its pathophysiology, diagnostic difficulties, and current therapeutic approaches. Materials and Methods: A narrative review was conducted based on selected scientific publications indexed in PubMed, Scopus, and Google Scholar. The inclusion criteria included articles describing the pathophysiology, clinical features, diagnosis, and treatment of SLS in the context of SLE. Results: SLS is characterized by progressive dyspnea, diaphragmatic elevation, and restrictive defects on pulmonary function testing. The exact pathogenesis remains unclear but involves neuromuscular dysfunction, diaphragmatic weakness, pleural involvement, and potential autoantibody-mediated mechanisms. Diagnosis is challenging due to the absence of specific markers and requires exclusion of other causes. Treatment primarily includes corticosteroids and immunosuppressants, with adjunctive respiratory rehabilitation. Despite therapy, pulmonary restriction may persist. Conclusions: SLS remains an under-recognized and underdiagnosed complication of SLE. Increased clinical awareness and early diagnostic interventions are key to preventing long-term respiratory impairment. Future research is needed to establish standardized diagnostic protocols and treatment guidelines.

  • Open Access

    Non-Suicidal Self-Injury (NSSI) in Borderline Personality Disorder: Dynamic Mechanisms, Cascading Models, and Psychosocial Outcomes in the Context of Specialist Interventions

    by Yuliia Protsenko, Magdalena Barczewska, Anna Marczak, Marta Kowalska, Dominika Bieszczad, Zuzanna Musialska, Olga Stadnicka, Marta Opalińska-Kubowicz, Marzena Swojnóg, Adam Mazurek, et al.

    Background. Non-suicidal self-injury (NSSI) occurs in 69-90% of women with borderline personality disorder (BPD) and represents a critical diagnostic criterion and therapeutic challenge. Despite its high prevalence and clinical significance, the dynamic psychological and neurobiological mechanisms underlying NSSI remain incompletely understood, and a substantial gap persists between acute symptom reduction and long-term psychosocial recovery. Aim. This study reviews NSSI in BPD, focusing on: identification of proximal psychological mechanisms and developmental factors influencing NSSI risk, and assessment of specialized therapeutic approaches' effectiveness in reducing NSSI and achieving sustained psychosocial functioning. Materials and Methods. A literature review was conducted using databases (PubMed, PsycINFO, and Google Scholar) for articles up to November 2025. Inclusion criteria focused on peer-reviewed studies examining NSSI in BPD populations using validated assessment tools. Results. Neuroimaging demonstrates that NSSI produces immediate amygdala deactivation, providing neurobiological reinforcement for this behavior. The Emotional Cascade Model identifies rumination instability and emotion differentiation deficits as key triggers for NSSI episodes. Childhood trauma dysregulates the HPA axis and correlates with functional deficits. Dialectical Behavior Therapy (DBT) shows a moderate effect size in reducing self-harm (Hedges' g = -0.622) and induces neuroplastic changes. Mentalization-Based Therapy (MBT) reduces suicide attempts, though social functioning often remains impaired even in long-term follow-up. Conclusions. Specialized psychotherapies effectively stabilize acute symptoms, but a clear gap persists between symptom control and functional recovery. Future research should adopt complex dynamic systems perspectives and prioritize outcomes reflecting social integration and quality of life.

  • Open Access

    Therapeutic potential of curcumin in dermatological conditions: mechanisms, clinical evidence and safety considerations

    by Olga Stadnicka, Kinga Popielarska, Marta Opalińska-Kubowicz, Zuzanna Musialska, Yuliia Protsenko, Marta Kowalska, Magdalena Barczewska, Anna Marczak, Dominika Bieszczad, Marzena Swojnóg, et al.

    Curcumin, a pleiotropic polyphenol derived from Curcuma longa, has gained considerable interest as a potential adjuvant therapy in dermatology due to its anti-inflammatory, antioxidant, antimicrobial and immunomodulatory properties. Preclinical studies demonstrate that curcumin modulates key molecular pathways involved in skin disease, including NF-κB, JAK–STAT, MAPK and Nrf2 signalling, affecting keratinocytes, fibroblasts, melanocytes, sebocytes and cutaneous immune cells. These findings have led to an increasing number of clinical studies investigating oral and topical curcumin, novel formulations and photodynamic applications across various dermatological conditions, such as psoriasis, atopic dermatitis, acne, pigmentary disorders, chronic wounds and photoaging. Clinical evidence suggests potential benefit as an adjunct to standard therapy in psoriasis, inflammatory and pruritic dermatoses, limited vitiligo and selected wound-healing settings, while data for cosmetic and infectious indications remain preliminary. Overall, curcumin shows a favourable safety profile, with mostly mild gastrointestinal or local adverse effects, though emerging reports of hepatotoxicity and drug interactions warrant caution with high-dose or long-term systemic use. Its clinical translation is limited by poor bioavailability, heterogeneous formulations, small and methodologically weak trials and lack of outcome standardisation. This narrative review summarises current mechanistic and clinical evidence, highlights limitations and identifies priorities for future research to better define curcumin’s role in modern dermatology.

  • Open Access

    Aerobic Exercise as an Essential Component of Non-Pharmacological Management for Metabolic Syndrome - A Review

    by Marzena Swojnóg, Magdalena Barczewska, Dominika Bieszczad, Barbara Reizer, Zofia Botto, Patrycja Felisiak, Dominika Kowalczyk, Zofia Śliwa, Dominik Andrzej Ślazyk, Klaudia Krystek

    Background. Metabolic Syndrome (MetS) is a prevalent cluster of conditions that significantly increases the risk of cardiovascular disease and type 2 diabetes mellitus. Lifestyle modification is universally recognized as the primary therapeutic strategy, with aerobic exercise playing a crucial role in improving metabolic health and reducing mortality risks in affected populations. Aim. This review synthesizes current evidence on the efficacy and mechanisms of aerobic exercise as a fundamental non-pharmacological strategy for managing Metabolic Syndrome (MetS). Material and methods. A search of major databases (2015–2025) was performed, focusing on systematic reviews and RCTs. Keywords included "Metabolic Syndrome," "aerobic exercise," "insulin resistance," "dyslipidemia," and "exercise prescription." Results. Regular aerobic exercise improves cardiometabolic risk factors independently of significant weight loss. It enhances insulin sensitivity via GLUT4 translocation, optimizes the lipid profile (reducing triglycerides, increasing HDL), and reduces visceral adiposity and inflammation. Additionally, High-Intensity Interval Training (HIIT) is highlighted as a potent strategy, often offering superior efficacy to moderate-intensity continuous training (MICT). Conclusions. Aerobic exercise is an essential component of MetS management. Professionals should prioritize individualized prescriptions, incorporating both MICT and HIIT, to effectively mitigate cardiometabolic risk and improve patient health.


  • Open Access

    Lipedema

    by Dominika Bieszczad, Magdalena Barczewska, Dominika Kowalczyk, Barbara Reizer, Klaudia Krystek, Patrycja Felisiak, Dominik Ślazyk, Zofia Botto, Marzena Swójnóg, Zofia Śliwa

    Background. Lipedema is a chronic and progressive fat disorder that affects ~11% of the female population. It is characterized by bilateral, disproportionate accumulation of subcutaneous adipose tissue predominantly in the lower body. Symptoms include pain, bruising, swelling, and subcutaneous nodules that are resistant to traditional interventions such as diet and exercise. Aim. The objective of this review is to summarize recent evidence on the characteristics, pathophysiology, diagnosis and treatment of lipedema. Matherial and Methods. A literature search was conducted using the PubMed database. The inclusion criteria were “full free text” and English scientific articles, published between 2015 and 2025. A total of 74 records were found, of which publications were ultimately included in the review. Results. Awareness of lipedema in the medical field is increasing, but its differential diagnosis still remains a challenge. Lipedema is often unrecognized or misdiagnosed as obesity or lymphedema. Conclusion. This narrative review provides a deeper understanding of lipedema as a serious condition, discusses its pathophysiology and treatment options. The data reveal advances in knowledge, particularly in conservative and surgical treatment with a focus on improving quality of life. However, there is a lack of scientific evidence confirming the safety and efficacy of various treatment methods. Further research is required to ensure the safety and increase the efficacy of treatment for this complex condition known as lipedema.

  • Open Access

    Paediatric Stroke: Diagnostic Strategies and Therapeutic Dillemas

    by Dominika Bieszczad, Magdalena Barczewska, Adam Mazurek, Kinga Popielarska, Marta Opalińska-Kubowicz, Zuzanna Musialska, Yuliia Prostenko, Marta Kowalska, Anna Marczak, Olga Stadnicka, et al.

    Background. Paediatric arterial ischemic stroke is a potentially disabling neurological condition that remains underrecognized due to its rarity and atypical clinical presentation. Diagnosis in children is often delayed because of heterogeneous symptoms and differences in stroke mechanisms compared with adults. Despite advances in neuroimaging and acute reperfusion therapies, evidence-based paediatric-specific diagnostic and treatment strategies remain limited. Aim. This review aimed to summarise current evidence regarding the epidemiology, pathophysiology, diagnostic approach, and management of acute ischemic stroke in the paediatric population. Material and methods. A narrative review of the literature was conducted using structured searches of PubMed, Google Scholar, and clinical guideline repositories. Articles published between 2015 and 2025 were included, comprising original studies, systematic reviews, meta-analyses, and international clinical guidelines focusing on risk factors, clinical presentation, neuroimaging, acute treatment, and secondary prevention. Results. Paediatric stroke differs substantially from adult stroke in etiology, clinical features, and outcomes. The most common causes include cerebral arteriopathies, congenital heart disease, infections, and haematological disorders such as sickle cell disease. Magnetic resonance imaging is the diagnostic modality of choice, with diffusion-weighted imaging and vessel wall imaging improving diagnostic accuracy. Intravenous thrombolysis and mechanical thrombectomy may be feasible and relatively safe in selected paediatric patients; however, high-quality evidence remains limited. Conclusion. Paediatric ischemic stroke remains a diagnostic and therapeutic challenge. Delayed recognition and heterogeneous mechanisms continue to limit optimal management. Further studies are needed to develop evidence-based paediatric guidelines and improve acute and long-term outcomes.

  • Open Access

    AN AGE-OLD PROBLEM IN A HIGH-TECH WORLD: THE DIGITAL HEALTH CARE DIVIDE FOR ELDERLY PATIENTS

    by Zofia Botto, Barbara Reizer, Marzena Swojnóg, Klaudia Krystek, Patrycja Felisiak, Dominika Kowalczyk, Dominika Bieszczad, Magdalena Barczewska, Zofia Śliwa, Dominik Andrzej Ślazyk

    The rapid digitalization of health care, propelled by the COVID-19 pandemic, has led to a rapidly growing gap in use of medical technology for senior patients. The inclusion of wearable medical devices, patient portals, telemedicine, and access to information has created an opportunity for patients to have more control over their health than ever before. However, for elderly patients it also comes with new challenges due to fear or reluctance to use advanced technologies they are not familiar with, leaving them to rely on family members and caregivers. It was found that health care provider’s hesitation in offering digital options and the expenses associated with digital devices are another obstacle. There is a significant need for modification in health care personnel attitudes regarding technology, promotion of combining community centers and health care for improving overall quality of life and digital literacy, and advocacy for senior patients' opinions when creating new medical technology and possibly incorporating AI technology to aid in bridging the gap.

  • Open Access

    THE DAWN PHENOMENON AND GLYCEMIC VARIABILITY MEASURED WITH CONTINUOUS GLUCOSE MONITORING

    by Marzena Swojnóg, Kinga Popielarska, Marta Opalińska-Kubowicz, Zuzanna Musialska, Yuliia Protsenko, Marta Kowalska, Magdalena Barczewska, Anna Marczak, Dominika Bieszczad, Olga Stadnicka, et al.

    The dawn phenomenon (DP), defined as an early-morning rise in glucose unrelated to preceding nocturnal hypoglycemia, represents a significant yet often underrecognized contributor to fasting hyperglycemia and overall glycemic instability in individuals with diabetes. The expansion of continuous glucose monitoring (CGM) technologies over the past decade has enabled more precise characterization of nocturnal glucose patterns, offering new insights into the prevalence, magnitude, and clinical implications of DP across diverse glycemic states. This review synthesizes original observational, retrospective, and prospective studies published between 2010 and 2025 that used CGM to evaluate DP in type 1 diabetes, type 2 diabetes, impaired glucose tolerance, and non-diabetic populations. Data extraction focused on DP definitions, nocturnal glucose trajectories, glycemic variability metrics, associations with HbA1c and time-in-range, and emerging evidence linking severe DP to adverse clinical outcomes. Findings indicate that DP is highly prevalent in both type 1 and type 2 diabetes, with magnitude varying widely depending on residual β-cell function, insulin sensitivity, and methodological differences in CGM-based definitions. DP correlates with increased total glucose exposure and greater glycemic variability, and may influence long-term metabolic risk. Understanding DP within the context of CGM-derived metrics is essential for optimizing individualized therapeutic strategies and improving morning glycemic control. Further standardized research is required to unify definitions and clarify the prognostic significance of DP.

  • Open Access

    GLOBAL LONGITUDINAL STRAIN AND 3D ECHOCARDIOGRAPHY FOR EARLY DETECTION OF ANTHRACYCLINE-INDUCED SUBCLINICAL CARDIOTOXICITY: NARRATIVE REVIEW

    by Marta Kowalska, Kinga Popielarska, Marta Opalińska-Kubowicz, Zuzanna Musialska, Yuliia Protsenko, Magdalena Barczewska, Anna Marczak, Dominika Bieszczad, Olga Stadnicka, Marzena Swojnóg, et al.

    Introduction and purpose: Anthracyclines are highly effective chemotherapeutic agents but carry a significant risk of dose-dependent cardiac toxicity, often progressing silently before left-ventricular ejection fraction (LVEF) declines. The objective of this review was to evaluate the role of three-dimensional echocardiography (3D-ECHO) and global longitudinal strain (GLS) in the early detection of subclinical anthracycline-induced cardiotoxicity and to compare their diagnostic performance with conventional 2D-LVEF assessment. Methods: A narrative review was conducted using clinical and observational studies indexed in PubMed over the last ten years. Only peer-reviewed human research evaluating anthracycline-induced cardiotoxicity was included. Studies comparing 2D-LVEF with 3D-LVEF and/or global longitudinal strain (GLS), as well as those assessing early markers of subclinical left-ventricular dysfunction, were selected. Extracted data focused on diagnostic effectiveness, time-to-detection of myocardial injury, and prognostic relevance of strain-based parameters. Conclusion: GLS and 3D-echocardiography outperform conventional 2D-LVEF in identifying early, subclinical anthracycline-related cardiotoxicity. GLS provides the highest sensitivity for early myocardial injury, while 3D-STE enhances spatial assessment and detects dysfunction before EF decline. Routine integration of these modalities into cardio-oncology surveillance may enable earlier intervention, prevent irreversible damage, and improve long-term cardiac outcomes.